An Economist’s Perspective on Exploitative Abuse of Dominant Position and Excluding Competitors
Share
Expert economists Valerie Meunier, Rameet Sangha and David Sevy authored a chapter for Global Competition Review's second edition of The Guide to Life Sciences.
Introduction
This chapter addresses the following competition issues, from an economist’s perspective, as they relate to the pharmaceutical industry:
- Exploitative abuse of a dominant position through excessive pricing; and
- Excluding actual or potential/nascent competitors via:
- Rebates and discounts; and
- Killer acquisitions.
This article was originally published by GCR here. The views expressed are those of the authors only and do not necessarily represent the views of Compass Lexecon, its management, its subsidiaries, its affiliates, its employees, or clients.
Meunier, V., Sangha, R., and Sevy, D. (2022): An Economist’s Perspective on Exploitative Abuse of Dominant Position and Excluding Competitors Through Killer Acquisitions. The Guide to Life Sciences, Second Edition.